Cancer nanomedicine meets immunotherapy: opportunities and challenges

被引：57

作者：

Sun, Qingxue ^{[1
,2
]}

Bai, Xiangyang ^{[1
,2
]}

Sofias, Alexandros Marios ^{[1
,2
]}

van der Meel, Roy ^{[3
,4
]}

Ruiz-Hernandez, Eduardo ^{[5
]}

Storm, Gert ^{[6
,7
]}

Hennink, Wim E. ^{[6
]}

De Geest, Bruno ^{[8
]}

Kiessling, Fabian ^{[1
,2
,9
]}

Yu, Hai-jun ^{[10
,11
]}

Lammers, Twan ^{[1
,2
,6
,7
]}

Shi, Yang ^{[1
,2
]}

机构：

[1] Rhein Westfal TH Aachen, Inst Expt Mol Imaging, Uniklin RWTH Aachen, Aachen, Germany

[2] Rhein Westfal TH Aachen, Helmholtz Inst Biomed Engn, Fac Med, Aachen, Germany

[3] Eindhoven Univ Technol, Dept Biomed Engn, Lab Chem Biol, Eindhoven, Netherlands

[4] Eindhoven Univ Technol, Inst Complex Mol Syst, Eindhoven, Netherlands

[5] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland

[6] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands

[7] Univ Twente, MIRA Inst Biomed Technol & Tech Med, Dept Targeted Therapeut, Enschede, Netherlands

[8] Univ Ghent, Dept Pharmaceut, Ghent, Belgium

[9] Inst Med Image Comp, Fraunhofer MEVIS, Aachen, Germany

[10] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China

[11] Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China

来源：

ACTA PHARMACOLOGICA SINICA | 2020年 / 41卷 / 07期

基金：

欧洲研究理事会; 中国国家自然科学基金;

关键词：

nanomedicine; immunotherapy; targeting; combination therapy; clinical translation; IMMUNOGENIC CELL-DEATH; T-CELLS; NANOPARTICLES; MICROENVIRONMENT; DELIVERY; SYSTEMS;

D O I：

10.1038/s41401-020-0448-9

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly preclinically but also already in clinical trials. Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle, via potentiating key steps in the immune reaction cascade, namely antigen release, antigen processing, antigen presentation, and immune cell-mediated killing. Combination nano-immunotherapy can be realized via three targeting strategies, i.e., by targeting cancer cells, targeting the tumor immune microenvironment, and targeting the peripheral immune system. The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel (Abraxane (R)) was combined with atezolizumab (Tecentriq (R)) for the treatment of patients suffering from advanced triple-negative breast cancer. In the present paper, besides strategies and initial (pre)clinical success stories, we also discuss several key challenges in nano-immunotherapy. Taken together, nanomedicines combined with immunotherapy are gaining significant attention, and it is anticipated that they will play an increasingly important role in clinical cancer therapy.

引用

页码：954 / 958

页数：5

共 46 条

[1]

[Anonymous], NAT REV CANC

[2]

[Anonymous], 2018, NAT REV DRUG DISCOV

[3] Complexity and simplification in the development of nanomedicines [J].